BMRN
Price
$58.98
Change
-$0.11 (-0.19%)
Updated
Sep 3, 04:59 PM (EDT)
Capitalization
11.33B
48 days until earnings call
SYRE
Price
$16.81
Change
+$0.18 (+1.08%)
Updated
Sep 3 closing price
Capitalization
1.02B
63 days until earnings call
Interact to see
Advertisement

BMRN vs SYRE

Header iconBMRN vs SYRE Comparison
Open Charts BMRN vs SYREBanner chart's image
BioMarin Pharmaceutical
Price$58.98
Change-$0.11 (-0.19%)
Volume$41.99K
Capitalization11.33B
Spyre Therapeutics
Price$16.81
Change+$0.18 (+1.08%)
Volume$293.94K
Capitalization1.02B
BMRN vs SYRE Comparison Chart in %
Loading...
BMRN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BMRN vs. SYRE commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMRN is a StrongBuy and SYRE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (BMRN: $59.09 vs. SYRE: $16.63)
Brand notoriety: BMRN and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BMRN: 88% vs. SYRE: 83%
Market capitalization -- BMRN: $11.33B vs. SYRE: $1.02B
BMRN [@Biotechnology] is valued at $11.33B. SYRE’s [@Biotechnology] market capitalization is $1.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BMRN’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • BMRN’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, BMRN is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BMRN’s TA Score shows that 6 TA indicator(s) are bullish while SYRE’s TA Score has 5 bullish TA indicator(s).

  • BMRN’s TA Score: 6 bullish, 2 bearish.
  • SYRE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, BMRN is a better buy in the short-term than SYRE.

Price Growth

BMRN (@Biotechnology) experienced а +2.85% price change this week, while SYRE (@Biotechnology) price change was -2.52% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +16.10%, and the average quarterly price growth was +32.67%.

Reported Earning Dates

BMRN is expected to report earnings on Oct 22, 2025.

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BMRN($11.3B) has a higher market cap than SYRE($1.02B). BMRN has higher P/E ratio than SYRE: BMRN (17.40) vs SYRE (1.68). BMRN YTD gains are higher at: -10.102 vs. SYRE (-28.565). BMRN has higher annual earnings (EBITDA): 934M vs. SYRE (-222.15M). BMRN has more cash in the bank: 1.43B vs. SYRE (527M). SYRE has less debt than BMRN: SYRE (0) vs BMRN (604M). BMRN has higher revenues than SYRE: BMRN (3.06B) vs SYRE (0).
BMRNSYREBMRN / SYRE
Capitalization11.3B1.02B1,111%
EBITDA934M-222.15M-420%
Gain YTD-10.102-28.56535%
P/E Ratio17.401.681,033%
Revenue3.06B0-
Total Cash1.43B527M272%
Total Debt604M0-
FUNDAMENTALS RATINGS
BMRN vs SYRE: Fundamental Ratings
BMRN
SYRE
OUTLOOK RATING
1..100
1710
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
72
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
6598
PRICE GROWTH RATING
1..100
6363
P/E GROWTH RATING
1..100
9983
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BMRN's Valuation (54) in the Biotechnology industry is in the same range as SYRE (72) in the Pharmaceuticals Major industry. This means that BMRN’s stock grew similarly to SYRE’s over the last 12 months.

BMRN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that BMRN’s stock grew similarly to SYRE’s over the last 12 months.

BMRN's SMR Rating (65) in the Biotechnology industry is somewhat better than the same rating for SYRE (98) in the Pharmaceuticals Major industry. This means that BMRN’s stock grew somewhat faster than SYRE’s over the last 12 months.

BMRN's Price Growth Rating (63) in the Biotechnology industry is in the same range as SYRE (63) in the Pharmaceuticals Major industry. This means that BMRN’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's P/E Growth Rating (83) in the Pharmaceuticals Major industry is in the same range as BMRN (99) in the Biotechnology industry. This means that SYRE’s stock grew similarly to BMRN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BMRNSYRE
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
86%
Momentum
ODDS (%)
Bullish Trend 2 days ago
62%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
68%
Bearish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
57%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
54%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 2 days ago
60%
Bullish Trend 8 days ago
85%
Declines
ODDS (%)
Bearish Trend 9 days ago
61%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bullish Trend 2 days ago
46%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
BMRN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SNWCX60.090.02
+0.03%
Easterly Snow Small Cap Value C
NBNGX25.85-0.05
-0.19%
Sit Mid Cap Growth
TQAIX46.13-0.13
-0.28%
T. Rowe Price Integrated US Sm Gr Eq I
OALVX20.17-0.09
-0.44%
Optimum Large Cap Value A
PSTAX21.21-0.24
-1.12%
Virtus KAR Capital Growth A

BMRN and

Correlation & Price change

A.I.dvisor indicates that over the last year, BMRN has been loosely correlated with ITOS. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if BMRN jumps, then ITOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMRN
1D Price
Change %
BMRN100%
+1.41%
ITOS - BMRN
49%
Loosely correlated
N/A
IONS - BMRN
42%
Loosely correlated
+34.84%
IBO - BMRN
42%
Loosely correlated
+3.47%
DNTH - BMRN
40%
Loosely correlated
+1.19%
SYRE - BMRN
40%
Loosely correlated
+0.85%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with IDYA. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+0.85%
IDYA - SYRE
61%
Loosely correlated
+3.79%
CGON - SYRE
60%
Loosely correlated
+2.39%
BEAM - SYRE
58%
Loosely correlated
-0.31%
XNCR - SYRE
57%
Loosely correlated
+5.17%
CRNX - SYRE
56%
Loosely correlated
+7.45%
More